Immunotech Biopharm Ltd
HKEX:6978.HK
1.6 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 52.161 | 58.448 | 353.341 | 845.386 | 282.247 | 128.332 |
| Short Term Investments
| 124.812 | 21.01 | 163.013 | 131.837 | 0 | 45.69 |
| Cash and Short Term Investments
| 176.973 | 79.458 | 353.341 | 845.386 | 282.247 | 174.022 |
| Net Receivables
| 0 | 0 | 47.994 | 34.328 | 0 | 0 |
| Inventory
| 4.924 | 7.213 | 10.866 | 3.975 | 4.81 | 2.291 |
| Other Current Assets
| 31.997 | 31.443 | -0.002 | 0.034 | 21.093 | 9.448 |
| Total Current Assets
| 213.894 | 118.114 | 412.2 | 883.723 | 308.15 | 185.761 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 500.759 | 527.251 | 426.588 | 154.492 | 85.35 | 78.747 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 41.882 | 42.486 | 14.25 | 7.371 | 7.767 | 2.575 |
| Goodwill and Intangible Assets
| 41.882 | 42.486 | 14.25 | 7.371 | 7.767 | 2.575 |
| Long Term Investments
| -78.45 | 119.165 | 0.163 | 0.132 | 0 | 0 |
| Tax Assets
| 124.812 | -119.165 | -0.163 | -0.132 | 0 | 0 |
| Other Non-Current Assets
| 168.199 | 191.586 | 244.651 | 164.643 | 15.704 | 12.13 |
| Total Non-Current Assets
| 632.39 | 761.323 | 685.489 | 326.506 | 108.821 | 93.452 |
| Total Assets
| 846.284 | 879.437 | 1,097.689 | 1,210.229 | 416.971 | 279.213 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 46.76 | 37.394 | 32.152 | 5.84 | 4.632 | 0.752 |
| Short Term Debt
| 24.679 | 26.056 | 20.209 | -7.83 | 3.786 | 2.896 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 15.034 | 19.212 | -2.896 |
| Other Current Liabilities
| 131.997 | 145.024 | 127.74 | 3.539 | 178.54 | 15.376 |
| Total Current Liabilities
| 203.436 | 208.474 | 180.101 | 31.617 | 206.17 | 19.024 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 432.494 | 123.75 | 90.845 | 43.856 | 35.214 | 30.958 |
| Deferred Revenue Non-Current
| 39.464 | 40.844 | 3.564 | 5.908 | 5.252 | 12.934 |
| Deferred Tax Liabilities Non-Current
| 0 | 0.001 | 5.8 | -2.504 | -1.138 | -8.11 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 5.908 | 5.252 | 12.934 |
| Total Non-Current Liabilities
| 471.958 | 164.594 | 94.409 | 49.764 | 40.466 | 43.892 |
| Total Liabilities
| 675.394 | 373.068 | 274.51 | 81.381 | 246.636 | 62.916 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0.172 | 63.146 |
| Common Stock
| 3.576 | 3.576 | 3.576 | 3.576 | 0.677 | 0.069 |
| Retained Earnings
| -1,618.146 | -1.283 | -0.965 | -0.611 | -0.172 | -63.146 |
| Accumulated Other Comprehensive Income/Loss
| 385.687 | 0.386 | 0.381 | 0.332 | -0 | -19.566 |
| Other Total Stockholders Equity
| 1,402.499 | 1,402.499 | 1,402.499 | 1,402.498 | 159.286 | -63.146 |
| Total Shareholders Equity
| 173.616 | 508.435 | 822.259 | 1,127.537 | 168.942 | 214.651 |
| Total Equity
| 170.89 | 506.369 | 823.179 | 1,128.848 | 170.335 | 216.297 |
| Total Liabilities & Shareholders Equity
| 846.284 | 879.437 | 1,097.689 | 1,210.229 | 416.971 | 279.213 |